coronavirus
cov
positivesens
singlestrand
rna
virus
infect
wide
rang
anim
host
human
cov
recogn
typic
caus
cold
pneumonia
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
zoonot
sourc
although
sar
epidem
control
public
health
measur
within
year
emerg
viru
spread
countri
associ
mortal
rate
effort
treat
sar
patient
exist
antivir
conclus
provid
clinic
benefit
may
even
worsen
diseas
merscov
continu
circul
middl
east
case
fatal
rate
approach
http
wwwwhointemergenciesmerscoven
current
fdaapprov
antivir
vaccin
treatment
prevent
merscov
infect
support
care
prevent
complic
constitut
current
standard
treatment
patient
emphas
need
directact
antivir
furthermor
sar
merslik
bat
cov
circul
natur
replic
effici
primari
human
airway
cell
use
cellular
receptor
entri
human
cov
immin
threat
human
emerg
underscor
need
broadli
activ
antivir
combat
cov
may
emerg
nucleosid
analogu
commonli
target
viral
replic
particularli
viral
dna
rna
polymeras
succeed
clinic
treat
multipl
viral
infect
howev
identif
develop
antivir
nucleosid
coronavirus
hamper
presenc
uniqu
cov
proofread
exoribonucleas
exon
nucleosid
analogu
inhibit
cov
sever
previous
test
nucleosid
analogu
incap
potent
inhibit
cov
replic
other
demonstr
poor
select
index
shown
cov
resist
mutagen
ribavirin
rbv
vitro
attribut
remov
proofread
exon
support
hypothesi
effect
nucleosid
analogu
must
evad
proofread
success
interfer
cov
rna
synthesi
recent
report
monophosphoramid
prodrug
cadenosin
nucleosid
analogu
fig
inhibit
sarscov
merscov
bat
cov
strain
capabl
replic
primari
human
airway
epitheli
cell
mediat
entri
use
human
cov
receptor
also
demonstr
prophylact
therapeut
efficaci
sarscov
diseas
mous
model
howev
studi
design
defin
report
potenti
pathway
implic
resist
viru
fit
virul
studi
demonstr
efficaci
cov
virus
includ
ebolaviru
describ
resist
mutat
use
model
murin
hepat
viru
mhv
demonstr
dramat
inhibit
viral
replic
viral
rna
synthesi
wildtyp
wt
viru
exon
mutant
lack
proofread
demonstr
increas
suscept
passag
wt
mhv
parent
nucleosid
result
phenotyp
resist
associ
two
nonsynonym
mutat
predict
finger
domain
rnadepend
rna
polymeras
engin
mutat
mhv
clone
background
close
recapitul
partial
resist
phenotyp
restor
rna
level
presenc
howev
resist
virus
could
compet
wt
mhv
vitro
coinfect
passag
absenc
introduct
homolog
substitut
mouseadapt
sarscov
confer
resist
similar
seen
mhv
also
attenu
vivo
pathogenesi
sarscov
mous
model
overal
result
consist
rnadepend
rna
polymeras
rdrp
mediat
mechan
potent
cov
inhibit
even
set
intact
exonmedi
proofread
cnucleosid
fig
shown
inhibit
multipl
viru
famili
vitro
determin
inhibit
model
cov
murin
hepat
viru
mhv
infect
delay
brain
tumor
dbt
cell
mhv
treat
increas
concentr
drug
observ
dosedepend
reduct
viral
titer
decreas
fig
halfmaximum
effect
concentr
valu
result
treatment
fig
observ
minim
detect
cytotox
within
test
rang
concentr
result
cytotox
fig
result
select
index
demonstr
inhibit
mhv
next
test
monophosphoramid
prodrug
fig
treatment
increas
concentr
result
decreas
viral
titer
viru
undetect
plaqu
assay
concentr
fig
inhibit
mhv
potent
fig
consist
higher
cellular
permeabl
effici
metabol
prodrug
activ
nucleosid
triphosph
bypass
ratelimit
first
phosphoryl
step
also
observ
minim
cytotox
concentr
requir
antivir
activ
line
previous
report
extens
cytotox
studi
relev
human
cell
type
valu
fig
result
select
index
result
expand
breadth
inhibit
cov
includ
model
cov
mhv
primari
human
airway
epitheli
cell
hae
cultur
among
clinic
relev
vitro
model
lung
recapitul
cellular
complex
physiolog
epithelium
human
conduct
airway
previou
result
demonstr
inhibit
viral
titer
multipl
cov
model
assess
potenc
effect
delay
treatment
compound
thu
determin
valu
treatment
sarscov
merscovinfect
hae
cultur
mean
valu
virus
approxim
fig
delay
addit
hour
h
postinfect
result
decreas
viral
titer
hae
cultur
sarscov
fig
merscov
fig
h
postinfect
measur
cellular
toxic
observ
hae
cultur
either
compound
tabl
result
demonstr
similar
high
potenc
across
diverg
cov
support
util
model
mhv
system
studi
inhibit
resist
predict
mechan
action
incorpor
activ
triphosph
viral
rna
therefor
test
hypothesi
would
inhibit
cov
earli
step
replic
inhibit
viral
rna
synthesi
determin
stage
viral
replic
cycl
inhibit
cov
infect
cell
mhv
multipl
infect
moi
pfucel
mhv
result
singlecycl
infect
treat
interv
h
preinfect
h
postinfect
observ
maxim
inhibit
ad
h
preinfect
h
postinfect
less
inhibit
detect
ad
h
postinfect
inhibit
observ
ad
h
postinfect
fig
result
demonstr
inhibit
cov
earli
step
infect
viral
rna
synthes
earli
infect
implic
inhibit
viral
rna
synthesi
next
determin
cellular
level
viral
rna
realtim
quantit
pcr
qpcr
treatment
treatment
increas
concentr
result
decreas
viral
rna
level
correl
decreas
titer
observ
fig
result
suggest
inhibit
cov
earli
infect
interf
viral
rna
replic
shown
profound
resist
cov
nucleosid
base
analogu
rbv
due
proofread
exon
engin
exon
mutant
mhv
sarscov
profoundli
sensit
compound
therefor
compar
sensit
wt
exon
mhv
exon
mhv
demonstr
greater
reduct
viral
titer
compar
wt
viru
fig
calcul
exon
viru
experi
decreas
compar
wt
fig
increas
sensit
exon
viru
similar
nucleosid
analogu
suggest
incorpor
viral
rna
remov
exon
howev
result
also
suggest
fundament
differ
relationship
cov
replicas
andor
templat
rna
compar
nucleosid
ribavirin
sinc
potent
inhibit
cov
intact
proofread
next
sought
identifi
target
inhibit
three
lineag
wt
mhv
serial
passag
presenc
increas
concentr
chosen
passag
select
metabol
activ
triphosph
metabolit
provid
larger
work
rang
concentr
two
lineag
demonstr
increas
viral
cytopath
effect
cpe
passag
lost
passag
passag
observ
increas
abil
one
passag
lineag
replic
presenc
determin
increas
viral
cpe
fullgenom
sequenc
viral
rna
reveal
nonsynonym
mutat
four
viral
proteincod
region
fig
helicas
phosphodiesteras
spike
glycoprotein
rdrp
fig
molecular
model
mhv
rdrp
predict
residu
resid
within
predict
finger
domain
conserv
righthand
structur
rdrp
fig
addit
residu
ident
across
sequenc
fig
base
known
role
polymeras
mutat
resist
nucleosid
analogu
virus
previou
work
describ
inhibit
respiratori
syncyti
viru
rsv
polymeras
first
engin
recov
recombin
mhv
contain
rdrp
mutat
determin
necessari
suffici
observ
resist
phenotyp
viru
popul
recombin
mhv
contain
either
individu
less
sensit
wt
mhv
still
sensit
viru
popul
across
broad
rang
concentr
contrast
mhv
encod
demonstr
resist
pattern
compar
fig
neither
viru
popul
recombin
virus
complet
resist
virus
remain
sensit
higher
nontox
concentr
compar
wt
mhv
viru
show
resist
viru
demonstr
resist
combin
mutat
mediat
resist
base
valu
tabl
decreas
viral
rna
level
next
test
resist
mutat
restor
rna
synthesi
observ
rdrp
resist
mutat
partial
restor
rna
level
presenc
degre
restor
rna
level
correl
fold
resist
fig
togeth
result
consist
mechan
action
primarili
target
rdrpmediat
rna
synthesi
assess
effect
resist
viral
fit
first
determin
replic
capac
recombin
mhv
carri
mutat
virus
replic
similarli
wt
mhv
replic
kinet
observ
peak
titer
fig
next
test
competit
fit
mhv
compar
wt
mhv
coinfect
multipl
passag
murin
dbt
cell
coinfect
wt
mhv
mhv
wtmutant
ratio
absenc
infect
cultur
supernat
serial
passag
time
fresh
cell
monolay
passag
mhv
outcompet
wt
mhv
popul
everi
input
ratio
fig
demonstr
competit
fit
cost
mutat
absenc
competit
fit
cost
suggest
resist
mutat
persist
absenc
treatment
given
complet
conserv
residu
across
cov
next
test
whether
substitut
homolog
sarscov
residu
could
confer
resist
recov
sarscov
carri
homolog
substitut
test
recov
mutant
virus
resist
cell
wt
sarscov
demonstr
dosedepend
inhibit
fig
recombin
viru
inhibit
repres
resist
fig
nearli
ident
fold
resist
mhv
result
support
conclus
conserv
residu
across
diverg
cov
reflect
conserv
function
impair
potenti
impli
common
pathway
resist
across
cov
gain
insight
pathogen
potenti
virus
directli
compar
wt
sarscov
sarscov
follow
nonleth
highdos
pfu
lowdos
pfu
inocul
wellcharacter
mous
model
sarscov
pathogenesi
diseas
reminisc
observ
human
mice
infect
high
dose
sarscov
lost
significantli
less
weight
p
wt
sarscovinfect
mice
fig
day
postinfect
mous
lung
viral
titer
similar
wt
sarscov
day
postinfect
lung
viral
titer
significantli
reduc
p
mice
infect
sarscov
fig
togeth
data
demonstr
sarscov
attenu
abil
caus
diseas
replic
less
effici
wt
viru
robust
mous
model
human
sarscov
diseas
nucleosid
analogu
multipl
mechan
action
includ
lethal
mutagenesi
oblig
nonoblig
chain
termin
perturb
natur
nucleotid
triphosph
pool
via
inhibit
nucleotid
biosynthesi
report
caus
prematur
termin
nascent
rna
transcript
purifi
rsv
polymeras
mechan
inhibit
viral
polymeras
fulli
explor
data
demonstr
act
earli
infect
decreas
rna
level
dosedepend
manner
parallel
impair
viral
titer
highli
activ
wt
cov
activ
mhv
lack
proofread
activ
exon
final
time
activ
cov
test
result
consist
report
metabol
effici
triphosph
metabolit
find
support
mechan
involv
incorpor
nascent
cov
rna
discrimin
chain
termin
incorpor
mutagenesi
fact
nucleosid
analogu
multipl
propos
mechan
viru
inhibit
includ
favipiravir
influenza
viru
rbv
hcv
futur
studi
use
deep
sequenc
biochem
approach
allow
us
precis
defin
mechan
action
cov
nucleosid
analogu
approv
treat
varieti
rna
dna
virus
cov
refractori
inhibit
nucleosid
analogu
resist
potent
inhibit
rbv
attribut
cov
proofread
exoribonucleas
previous
report
mhv
sarscov
strain
lack
proofread
activ
exon
exon
sensit
rbv
underscor
role
exonmedi
proofread
resist
inhibit
compound
result
suggest
effect
inhibit
cov
nucleosid
analogu
would
need
inhibit
exon
directli
incorpor
effici
elong
reaction
much
faster
exon
cleavag
reaction
recogn
exonmedi
remov
latter
mechan
propos
sensit
herp
simplex
viru
hsv
acyclovir
specif
hsv
exonucleas
unabl
remov
acyclovir
show
exon
mhv
sensit
wt
mhv
treatment
result
suggest
recogn
least
partial
function
exon
exon
activ
suffici
prevent
potent
inhibit
cov
replic
one
possibl
explan
may
recogn
remov
exon
less
effici
mutagen
incorrect
nucleotid
though
studi
need
fulli
understand
role
exon
inhibit
cov
overal
enhanc
activ
monophosph
prodrug
increas
sensit
exon
virus
inhibit
select
resist
mutat
model
rdrp
finger
domain
timedepend
viral
inhibit
profil
decreas
viral
rna
level
support
hypothesi
directli
inhibit
viral
rna
synthesi
previou
studi
assess
inhibit
multipl
virus
none
report
resist
mutat
treatment
studi
passag
mhv
presenc
result
select
resist
sequenc
identifi
consensu
nonsynonym
mutat
core
polymerasecod
region
similar
level
resist
observ
homolog
substitut
sarscov
mutat
immedi
vicin
rdrp
activ
site
mechan
resist
remain
determin
residu
conserv
across
cov
suggest
mediat
conserv
function
sequenc
align
molecular
model
cov
rdrp
predict
lie
within
motif
f
finger
domain
form
channel
incom
ntp
contact
templat
within
defin
structur
motif
also
resid
finger
domain
resist
mutat
nucleosid
analogu
includ
lie
finger
domain
implic
alter
replic
fidel
mechan
resist
picornavirus
hiv
previou
studi
use
homolog
model
cov
rdrp
base
coxsackieviru
rdrp
structur
predict
confirm
substitut
mhv
rdrp
increas
cov
fidel
exon
virus
suggest
viral
replic
fidel
modul
may
also
impact
suscept
support
result
highli
activ
wt
viru
even
potent
absenc
exon
proofread
activ
howev
cov
replicas
encod
mani
protein
mutat
may
alter
proteinprotein
interact
among
compon
avail
vitro
biochem
system
demonstr
polymeras
exoribonucleas
activ
suggest
may
possibl
defin
specif
effect
resist
mutat
polymeras
rna
proofread
activ
thu
interest
determin
confer
classlevel
resist
nucleotid
analogu
gener
increas
fidel
chang
specif
nucleotid
select
alter
replicaseprotein
interact
novel
mechan
recombin
mhv
contain
mutat
close
recapitul
resist
phenotyp
passag
viru
popul
confirm
import
mutat
resist
howev
result
elimin
possibl
potenti
pathway
resist
may
exist
addit
also
identifi
addit
nonrdrp
mutat
consensu
sequenc
passag
viru
includ
anoth
compon
mhv
replicas
helicas
import
determin
protein
contribut
resist
well
use
probe
defin
protein
interact
function
within
viral
replicas
identif
resist
mutat
antivir
compound
candid
vitro
provid
opportun
assess
concern
resist
may
promot
viral
fit
lead
enhanc
transmiss
greater
diseas
sever
resist
mhv
slow
emerg
partial
suggest
high
genet
barrier
resist
similar
seen
hcv
resist
nucleotid
antivir
sofosbuvir
moreov
although
recombin
mhv
contain
replic
similarli
wt
parallel
cultur
resist
viru
fail
compet
wt
mhv
coinfect
multipl
passag
demonstr
fit
cost
associ
resist
mutat
may
limit
emerg
treatment
fit
impair
evidenc
vivo
attenu
viru
sarscov
mous
model
similar
report
virus
select
resist
nucleotid
analogu
includ
hiv
chikungunya
viru
fit
impair
may
due
alter
rna
replic
fidel
nucleotid
incorpor
protein
stabil
suggest
resist
lead
transmiss
pathogen
viru
summari
work
provid
evid
highli
activ
cov
high
genet
barrier
achiev
resist
addit
resist
viru
suffer
loss
competit
fit
vitro
attenu
anim
suggest
mutat
favor
diseas
emerg
like
poorli
maintain
natur
particularli
acut
infect
final
result
identifi
potenti
novel
determin
polymeras
function
nucleotid
select
fidel
guid
futur
structurefunct
biochem
studi
polymeras
mechan
togeth
result
argu
strongli
continu
clinic
develop
treat
merscov
demonstr
potenti
util
broadspectrum
treatment
cov
infect
murin
astrocytoma
delay
brain
tumor
dbt
cell
babi
hamster
kidney
cell
express
mhv
receptor
bhkr
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
invitrogen
penicillin
streptomycin
gibco
hepe
gibco
amphotericin
b
corn
bhkr
cell
supplement
mgml
mediatech
human
lung
epitheli
cell
line
clone
kindli
donat
c
tseng
univers
texa
medic
branch
maintain
dmem
gibco
fetal
bovin
serum
hyclon
gibco
antibioticantimycot
solut
human
tracheobronchi
epitheli
cell
obtain
airway
specimen
resect
patient
undergo
surgeri
univers
north
carolina
institut
review
boardapprov
protocol
cystic
fibrosi
center
tissu
cultur
core
unc
tissu
core
primari
cell
expand
gener
passag
cell
passag
cell
plate
densiti
cell
per
well
transwellcol
support
human
airway
epithelium
cultur
gener
provis
airliquid
interfac
ali
week
form
welldifferenti
polar
cultur
resembl
vivo
pseudostratifi
mucociliari
epithelium
work
mhv
perform
use
recombin
wt
strain
genbank
access
sarscov
express
green
fluoresc
protein
sarsgfp
merscov
express
red
fluoresc
protein
mersrfp
creat
molecular
cdna
clone
accord
protocol
describ
previous
synthes
gilead
scienc
inc
prepar
mm
stock
solut
dimethyl
sulfoxid
dmso
respect
cell
viabil
assess
use
celltiterglo
promega
plate
accord
manufactur
instruct
dbt
cell
incub
indic
concentr
compound
h
cell
viabil
determin
use
verita
micropl
luminomet
promega
valu
normal
untreat
cell
test
mhv
sensit
subconflu
monolay
dbt
cell
infect
indic
viru
multipl
infect
moi
pfu
per
cell
h
inoculum
remov
replac
medium
contain
indic
concentr
cell
supernat
harvest
h
postinfect
titer
determin
plaqu
assay
test
resist
capac
sarscov
cell
seed
plate
densiti
cellswel
h
prior
infect
medium
replac
fresh
medium
h
prior
infect
encourag
optim
cell
growth
cell
infect
sarscov
sarscovwtnanoluc
moi
pfucel
presenc
absenc
dilut
dmso
diluent
untreat
control
uvinactiv
viru
nanoluciferas
report
nanoluc
background
control
cell
lyse
incub
h
use
promega
nanoglo
assay
kit
assay
luminesc
plate
reader
spectramax
molecular
devic
valu
curv
gener
nonlinear
regress
curv
fit
graphpad
prism
softwar
la
jolla
ca
fulli
matur
hae
cultur
obtain
unc
tissu
core
h
prior
infect
apic
surfac
cultur
wash
phosphatebuff
salin
pb
h
cultur
move
well
contain
fresh
airliquid
interfac
ali
medium
immedi
prior
infect
pb
ad
apic
surfac
hae
cultur
min
first
wash
remov
second
wash
ad
prior
move
hae
cultur
ali
medium
contain
concentr
rang
indic
experi
second
wash
remov
viral
inoculum
moi
pfucel
mersrfp
sarsgfp
ad
apic
surfac
cultur
h
viral
inoculum
remov
apic
surfac
cultur
wash
three
time
pb
final
wash
remov
cultur
incub
total
h
postinfect
cultur
apic
wash
perform
pb
assess
viral
replic
titer
total
rna
collect
trizol
life
technologiesthermofish
frozen
prior
extract
realtim
pcr
analysi
data
shown
repres
duplic
sampl
set
perform
minimum
three
differ
patient
isol
therapeut
hae
experi
cultur
wash
describ
hae
cell
remain
drugfre
ali
medium
first
day
infect
h
postinfect
cultur
move
ali
medium
contain
concentr
rang
indic
cultur
harvest
h
postdrug
treatment
h
postinfect
subconflu
monolay
dbt
cell
infect
wt
mhv
moi
pfucel
h
viru
inoculum
remov
fresh
medium
contain
dmso
ad
indic
time
postinfect
supernat
harvest
h
postinfect
viral
titer
determin
plaqu
assay
subconflu
dbt
cell
infect
indic
viru
moi
pfucel
fig
pfucel
fig
inoculum
remov
h
incub
medium
contain
indic
concentr
ad
supernat
collect
total
rna
harvest
use
trizol
reagent
invitrogen
h
respect
viral
titer
determin
plaqu
assay
rna
revers
transcrib
use
superscript
iii
invitrogen
gener
cdna
quantifi
quantit
pcr
qpcr
previous
describ
wt
mhv
passag
triplic
increas
concentr
rang
infect
initi
passag
moi
pfucel
supernat
harvest
frozen
cell
monolay
demonstr
cytopath
effect
cpe
h
constant
volum
use
initi
subsequ
passag
lineag
maintain
passag
lineag
lost
respect
viru
cpe
reach
upon
multipl
effort
variou
concentr
lineag
demonstr
increas
visibl
cpe
thu
lineag
carri
passag
passag
total
rna
harvest
infect
cell
monolay
use
trizol
reagent
use
viral
popul
sequenc
passag
rna
extract
revers
transcrib
use
superscript
iii
follow
gener
amplicon
three
lineag
cover
passag
pcr
amplicon
cover
whole
genom
passag
lineag
dideoxi
amplicon
sequenc
perform
genhunt
nashvil
tn
analyz
identifi
mutat
use
macvector
residu
locat
previous
describ
mhv
rdrp
model
use
pymol
molecular
graphic
system
llc
multipl
sequenc
align
gener
use
macvector
quikchang
mutagenesi
perform
accord
manufactur
protocol
gener
mutat
mhv
individu
genom
cdna
fragment
plasmid
use
previous
describ
infecti
clone
reversegenet
system
mutant
recov
bhkr
cell
follow
electropor
vitrotranscrib
genom
rna
fragment
contain
mutat
well
viru
stock
sequenc
ensur
mutat
present
use
studi
genhunt
gener
sarscov
encod
resist
substitut
cassett
encod
substitut
synthes
biobas
inc
synthes
cassett
clone
sarscov
infecti
cdna
plasmid
uniqu
mlui
msti
site
subsequ
select
clone
sequenc
verifi
across
cassett
sarscov
express
resist
substitut
along
nanoluc
report
place
produc
describ
previous
subconflu
monolay
dbt
cell
infect
wt
virus
moi
pfucel
h
inocula
remov
cell
wash
pb
addit
prewarm
medium
supernat
harvest
indic
time
postinfect
titer
determin
plaqu
assay
subconflu
dbt
cell
coinfect
wt
mhv
input
ratio
moi
pfucel
h
viru
inoculum
remov
fresh
medium
ad
h
postinfect
viru
supernat
collect
infect
cell
monolay
harvest
use
trizol
reagent
sampl
frozen
cell
supernat
passag
onto
fresh
dbt
cell
total
four
passag
supernat
cell
monolay
trizol
collect
passag
nearli
monolay
involv
h
postinfect
rna
extract
revers
transcrib
use
superscript
iii
pcr
amplicon
cover
region
mutat
sequenc
genhunt
result
repres
combin
frequenc
mutat
determin
chromatograph
trace
analyz
use
macvector
group
old
femal
balbc
charl
river
inc
mice
anesthet
ketaminexylazin
intranas
infect
either
wildtyp
mouseadapt
sarscov
express
nanoluciferas
wt
sarscov
nanoluc
engin
harbor
resist
mutat
sarscov
anim
weigh
daili
monitor
virusassoci
weight
loss
day
postinfect
anim
per
group
sacrif
isofluran
overdos
inferior
right
lobe
harvest
frozen
titer
determin
plaqu
assay
describ
previous
cohort
monitor
day
postinfect
order
compar
kinet
recoveri
lung
sampl
harvest
titer
determin
describ
previou
sampl
statist
test
perform
use
graphpad
prism
softwar
la
jolla
ca
describ
respect
figur
legend
